The stock price of Iterum Therapeutics Plc (NASDAQ: ITRM) has jumped by 10.76 compared to previous close of 0.79. Despite this, the company has seen a gain of 18.16% in its stock price over the last five trading days. GlobeNewsWire reported 2023-11-07 that DUBLIN, Ireland and CHICAGO, Nov. 07, 2023 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company will release its third quarter 2023 financial results before the open of the U.S. financial markets on Tuesday, November 14, 2023. Management will host a conference call at 8:30 a.m. ET that day to discuss the Company’s financial results and provide an update on its business.
Is It Worth Investing in Iterum Therapeutics Plc (NASDAQ: ITRM) Right Now?
, and the 36-month beta value for ITRM is at 1.67. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The average price suggested by analysts for ITRM is $15.00, which is $14.12 above the current market price. The public float for ITRM is 12.66M, and currently, shorts hold a 0.39% of that float. The average trading volume for ITRM on November 16, 2023 was 29.17K shares.
ITRM’s Market Performance
ITRM stock saw an increase of 18.16% in the past week, with a monthly gain of 25.00% and a quarterly increase of -11.60%. The volatility ratio for the week is 12.55%, and the volatility levels for the last 30 days are 9.14% for Iterum Therapeutics Plc (ITRM). The simple moving average for the past 20 days is 22.29% for ITRM’s stock, with a -13.16% simple moving average for the past 200 days.
ITRM Trading at 19.22% from the 50-Day Moving Average
After a stumble in the market that brought ITRM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.18% of loss for the given period.
Volatility was left at 9.14%, however, over the last 30 days, the volatility rate increased by 12.55%, as shares surge +30.60% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.77% upper at present.
During the last 5 trading sessions, ITRM rose by +18.16%, which changed the moving average for the period of 200-days by -37.05% in comparison to the 20-day moving average, which settled at $0.7257. In addition, Iterum Therapeutics Plc saw 4.17% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at ITRM starting from Puttagunta Sailaja, who sale 3,365 shares at the price of $1.32 back on Dec 02. After this action, Puttagunta Sailaja now owns 4,969 shares of Iterum Therapeutics Plc, valued at $4,442 using the latest closing price.
Stock Fundamentals for ITRM
The total capital return value is set at -43.79, while invested capital returns managed to touch -65.18. Equity return is now at value -172.86, with -55.89 for asset returns.
Based on Iterum Therapeutics Plc (ITRM), the company’s capital structure generated 107.51 points at debt to equity in total, while total debt to capital is 51.81. Total debt to assets is 45.04, with long-term debt to equity ratio resting at 106.33. Finally, the long-term debt to capital ratio is 51.24.
The liquidity ratio also appears to be rather interesting for investors as it stands at 6.89.
In conclusion, Iterum Therapeutics Plc (ITRM) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.